ASH 2021 | How overall survival and primary causes of death have changed in patients with AL amyloidosis
Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, discusses some key findings from a 40-year longitudinal natural history study that provides information on how the survival outcome of patients with light chain (AL) amyloidosis has changed over the years. Dr Sanchorawala shares some insights on the increase in overall survival, reduction in early mortality, and changes in the primary causes of death observed in patients with systemic AL amyloidosis. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
Disclosures
Takeda: Research Funding; Celgene: Research Funding; Prothena: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Caelum: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Janssen: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Abbvie: Membership on an entity’s Board of Directors or advisory committees; Regeneron: Membership on an entity’s Board of Directors or advisory committees; Proclara: Membership on an entity’s Board of Directors or advisory committees; Pfizer: Honoraria; Karyopharm: Research Funding.
